A pproximately 8% of children in the United States have a food allergy (1, 2) , and the incidence is increasing (3, 4) . As with other complex diseases, the etiology of a food allergy phenotype likely arises from a combination of multiple genetic factors and environmental triggers (5) . Heritability studies suggest that genetic factors may play a significant role in predisposition to food allergy. An increased prevalence of peanut allergy was reported in siblings of affected children relative to the general population (6) , and estimates of the heritability from a twin study are as high as 81.6% (7) . Genetic susceptibility was reported previously through linkage studies (8, 9) , and several food allergy genes of interest have been identified through candidate gene studies (reviewed in Ref. 10) .
Copy number variations (CNVs) are defined as deletions, duplication, inversions, or complex rearrangements in genomic segments compared with the reference genome (5, 11) . They are generated through errors in recombination or DNA replication and repair (reviewed in Ref. 12) . When CNVs occur in functional areas of the genome, such as protein coding or regulatory regions, they can result in a phenotype through dysregulation of RNA levels (13) or by altering the structure of a gene and, hence, its protein product (14) .
In clinical practice, the identification of common CNVs underlying intellectual disability, autism spectrum disorders, and multiple congenital anomalies has had a major impact (reviewed in Ref. 15 ). In the allergy field, CNVs within the filaggrin gene were shown to contribute to atopic dermatitis risk in a dose-dependent manner (16) . No published study has examined CNVs in food allergy patients. In this study, our investigation of the association of CNVs in pediatric food allergy resulted in the identification of CNV enrichment in two genes that may contribute to food allergy susceptibility.
Materials and Methods

Research subjects
Individuals were selected from a population of research subjects from the Center for Applied Genomics. This population consisted of children recruited from the Children's Hospital of Philadelphia Health Care Network who permitted use of their health care records and genotyping data available at the center. Blood for genotyping was collected from phlebotomy collection sites within the hospital. Only individuals whose blood samples resulted in high-quality genome-wide genotyping data were included in our study.
Ethics statement
This study was approved by the institutional review board of the Children's Hospital of Philadelphia. All participants and/or their parents signed an informed consent allowing use of this information.
Food allergy population
Children with food allergy were first identified among research subjects if they had any of the following International Classification of Diseases, Ninth Revision codes of food allergy within their medical records: 693.1: food allergy, dermatitis due to food taken internally, or 995.7: other adverse food reactions NOS. Chart review was performed to verify candidacy. To be included as a case patient, an individual had to meet the following criteria: history consistent with food allergy documented by an allergy specialist [timing and symptoms after ingestion as per Sampson et al. (17) ]; food allergy sensitivity (as shown by IgE . 0.35 kU A /l or skin prick testing [.3 mm wheal]); and food allergen identified as milk, egg, peanut, tree nut, soy, wheat, fish, or shellfish.
Healthy controls
To be a control subject in our study, individuals could not have International Classification of Diseases, Ninth Revision codes attached to their chart that identified food allergy, as listed above. We selected controls with average ages older than the cases to reduce the possibility of an individual developing the disease at a later stage.
Genotyping
Genotyping of all cases and controls was performed at the Center for Applied Genomics, Children's Hospital of Philadelphia. Genotyping of food allergy cases and controls of the discovery cohort was done on the Illumina HumanHap550 BeadChip or Illumina Human610-Quad BeadChip. The change to the Human610-Quad BeadChip for analysis occurred after production of the HumanHap550 BeadChip ceased. Because the two chip types have .500,000 common single nucleotide polymorphisms (SNPs), data from the two chips could be combined and analyzed together. After production of the Human610-Quad BeadChip ceased, all subsequent samples were analyzed using the Illumina HumanOmniExpress-12 v1.0 chip. All food allergy cases and controls forming the replication cohort of our study were genotyped using this latest chip.
Principal component analysis
We used principal component analysis (PCA) to infer population structure among cases and controls, as well as to correct for potential population stratification. The principal components were generated on ancestryinformative markers using the EIGENSTRAT (18) software package.
CNV detection
For the discovery cohort, the ∼530,000 SNPs common to the Illumina HumanHap550 BeadChip or the Illumina Human610-Quad BeadChip were used for CNV calling. The PennCNV (19) software package was used to call CNVs based on the intensity data from the Illumina arrays, including the log R ratio (LRR) and the B allele frequency for each SNP. Because we focused on markers on the autosomes, 522,879 autosomal SNPs were used for CNV calling. Similarly, 712,726 autosomal SNPs on the Illumina HumanOmniExpress-12 v1.0 chip were used for CNV calling for the replication cohort.
CNV quality control
As described previously (20) , CNV metrics were reviewed, and samples with outlier values in the following categories were removed: call rate, cryptic relatedness between samples, intensity noise measured by the SD of LRR (LRR SD), intensity waviness measured by |GC base pair wave factor (GCWF)|, and high number of CNVs/sample. The distribution of the CNV metrics was plotted, the distribution plots typically display a linear phase and an exponential phase, and samples with CNV metrics falling into the exponential phase were removed. For both the discovery cohort and the replication cohort, samples with SNP call rate , 98% were excluded. One sample from each pair of duplicated or related samples, as defined by genome-wide identity-by-descent score (PI_HAT) . 0.30, was removed. Because of the SNP coverage differences among the Illumina HumanHap550 BeadChip, the Illumina Human610-Quad BeadChip, and the Illumina HumanOmniExpress-12 v1.0 chip, the quality control plots of the CNV metrics were reviewed separately for samples in the discovery cohort and those in the replication cohort. In the discovery cohort, samples with LRR SD . 0.3, |GCWF| . 0.05, or CNV count . 100 were excluded from further analysis. In the replication cohort, samples with LRR SD . 0.21, |GCWF| . 0.035, or CNV count . 100 were removed.
CNV association statistical analysis
We assessed the appropriate genome-wide multiple testing correction for our study. We focused on the association between phenotype and rare CNVs. The CNV association software ParseCNV (20) was used to detect the association between CNV region (CNVR) and the food allergy phenotype. ParseCNV used a genome-wide segment-based scoring approach. As described previously (20) , the Fisher exact test was used to compare the CNV frequency among cases and controls at each SNP. Among the discovery set of 522,879 autosomal SNPs shared by the Illumina HumanHap550 BeadChip and the Illumina Human610-Quad BeadChip, 1232 (0.236%) showed deletion and 320 (0.0612%) showed duplication in at least two unrelated cases in the discovery cohort (frequency $ 0.560%). The reason why we selected the cutoff of two cases having a given CNV is that it is the minimal case frequency that can produce nominal statistical significance and reproducibility for a CNV in a given region when compared with controls using the Fisher exact test. Such SNP-based upfront exclusion is analogous to the inclusion threshold of 1% minor allele frequency in SNP-based genome-wide association studies (GWASs). Subsequently, SNPs were collapsed into CNVRs that constitute the genomic span of consecutive probes in proximity (, 1 MB) with comparable significance (6 1 log p value) in the Fisher exact test when comparing case and control status (20) . In our study, SNPs were collapsed into 125 deletion and 32 duplication CNVRs, which means a total of 157 tests. Therefore, the genome-wide significant threshold is p , 3.18 3 10 24 , considering multiple testing correction. It is similar to the conservative cutoff of p = 5 3 10
24 that we discussed previously (http://parsecnv.sourceforge.net/ #MultipleTestingCorrection).
For logistic regression analysis, we first generated ped files for CNV status. In the deletion ped files, CNV genotype status was defined in the following way: 1 1 for CN = 0, 1 2 for CN = 1, and 2 2 for others. In the duplication ped file, CNV genotype status was defined as 1 1 for CN = 4, 1 2 for CN = 3, and 2 2 for others. This strategy of converting CNV status to "genotype" ped file was described in detail in our previous publication (20) . It allows for logistic regression analysis including the first three principal components to adjust for population stratification.
Permutation tests
To test for batch effects, we randomized the cases and controls between the discovery and replication cohorts and conducted permutation tests. Because of the SNP coverage differences between platforms, intensity data from the discovery cohort and replication cohort cannot be combined directly prior to CNV calling. Instead, we coded the genotype of samples carrying the significant CNVR of CTNNA3 as 1 2, because they are all heterozygous deletions, and genotype 2 2 for those normal diploids (CN = 2), as described above. Having converted the CNV calls to genotypes, we then combined all samples and conducted permutations by randomly shuffling case and control status. We similarly defined the RBFOX1 "genotype" ped based on whether each sample in the European ancestry cohort carries the significant CNVRs. Finally, we conducted 10,000 permutations of the data and a Fisher exact test for each permutation. Empirical p values were derived from the permutation tests.
Meta-analysis
We conducted meta-analysis of the overlapping CNVR or overlapping genes using the sample size-based analytical strategy implemented in METAL software (21) .
CNV validation
CNVs of interest were validated using TaqMan copy number probes (Life Technologies, Grand Island, NY), following the manufacturer's standard protocol.
Western blot analysis of CTNNA3 deletion
EBV-immortalized cell lines were generated from PBMCs of one case carrying the CTNNA CNVR and four samples without the deletion as controls. We followed the protocol as described (22) . For Western blot analysis of CTNNA3 expression, EBV cells were lysed with Nonidet P-40 lysis buffer (Invitrogen). Proteins were separated on 4-12% NuPAGE BisTris gels in MOPS SDS running buffer and transferred overnight onto nitrocellulose membranes (Invitrogen). The membrane was blocked in 3% BSA and cut into two halves. The top half was incubated with mouse anti-CTNNA3 mAb (Lifespan Biosciences), and the bottom half was incubated with mouse anti-b-actin mAb (Santa Cruz Biotechnology). Subsequently, the membranes were washed, incubated with secondary Ab for 1 h, and washed again; bound Ab was detected with a WesternBright ECL chemiluminescence detection system (Advansta).
CD63 basophil test
Ficoll-isolated mononuclear cells (which also contain substantial amounts of basophils) were used as the primary source of cells. Cells were nucleofected with control small interfering RNA (siRNA) and CTNNA3-specific Trilencer-27 Human siRNA (OriGene) at 10 nM using an Amaxa nucleofector and program Y-001. Forty-eight hours after nucleofection, cells were incubated with CD63-allophycocyanin and CD203c-PE Ab and PMA (10 ng/ml) for 30 min. After incubation, cells were washed and analyzed by FACS for expression of CD63 and CD203c. CTNNA3 knockdown (KD) was confirmed by immunoblot analysis. Lysates of 10 6 cells were separated by SDS-PAGE and evaluated for KD of CTNNA3. After transferring, the nitrocellulose membrane was cut into two halves. The top part was probed with mouse anti-CTNNA3 mAb, and the bottom half was probed with mouse anti-b-actin mAb as a loading control.
Results
After quality control screening, the discovery cohort consisted of 357 cases with diagnosed food allergy and 3980 controls, and the replication cohort consisted of 167 cases and 1573 controls. The demographic features of the two cohorts are summarized in Table I . PCAs of cases and controls (Supplemental Fig. 1 ) indicate that they overlapped in terms of ethnicity based on SNP genotype data. The majority of the participants in our study are of European ancestry, with a smaller set of African Americans who are an admixed population of European ancestry and African ancestry. We first used the Fisher exact test to statistically analyze CNV association and then conducted logistic regression, including principal components, to correct for potential population stratification.
The CNV profile of cases and controls is presented in Table II . In the discovery cohort, 5234 deletions and 2042 duplications were found in the cases, with an average of 14.66 deletions and 5.72 duplications/individual. This was not significantly different from the number of CNVs detected in the control set, suggesting that the overall CNV burden was the same between the cases and controls. Similarly, in the replication cohort there was no significant difference in the number of CNVs detected between cases and controls. The average length of deletions was similar between cases and controls in both the discovery cohort and the replication cohort. A lower average duplication size was observed in cases compared with controls in the discovery, but not the replication, cohort.
No large-scale unbiased genetic study has been reported in the food allergy research community, but there have been a few smallscale candidate gene studies; however, the results were not consistent with each other, as reviewed by Hong et al. (10) . We examined the following candidate genes in our study: HLA, CD14, FOXP3, STAT6, SPINK5, IL10, and IL13. Taking a gene-based approach, we assessed whether the ratio of samples carrying CNVs within one or more exons in these genes was significantly different between cases and controls using the Fisher exact test implemented in ParseCNV (20) . We did not observe any significant difference for any of these genes. Taking into account introns, HLA-B was the only gene for which the p value for rare CNVs of duplication was nominally significant in the replication cohort (p = 0.026) and marginally significant when the discovery cohort and replication cohort were combined (p = 0.063, two-sided). We observed two cases harboring duplications in the gene HLA-B at chr6:31300691-31304663 and three controls having duplications in this gene.
Next, we took a genome-wide segment-based scoring approach to identify CNVRs associated with food allergy. In our discovery cohort, we found 125 deletions and 32 duplications enriched in cases and 18 deletions and 10 duplications enriched in the controls.
We then examined which of the case-enriched CNVRs identified in our discovery cohort could also be identified in the independent replication cohort. Because the SNP coverage is different between the genotyping platforms used for the discovery cohort and for the replication cohort, and because of uncertainty about the CNVR boundaries, we expected that CNVRs that are commonly identified in both cohorts may only have partial overlap. We found five significant CNVRs in the discovery cohort that overlapped the CNVRs observed in the replication cohort (Table III) . Metaanalysis showed that three of them had p values surpassing the The Journal of Immunology genome-wide significant cutoff of p , 5 3 10
24
. However, each of these five regions was a deletion CNV in the discovery cohort but a duplication CNV in the replication cohort.
We next investigated whether any genes had significant CNVRs both in the discovery cohort and in the replication cohort and found five such genes (Table IV) . Among them, three genes reached genome-wide significance (p , 5 3 10 24 ) in the meta-analysis.
The top one is RBFOX1, which overlapped with a significant CNVR in three cases and two controls in the discovery cohort (Table IV) , as well as a significant CNVR in two cases and no controls in the replication cohort (Table IV) . Meta-analysis yielded a p value of 1.58 3 10
. Another gene of interest is CTNNA3, because exon 11 of CTNNA3 overlapped with the significant CNVR identified in 2 of 357 cases and 2 of 3980 controls in the discovery cohort (Fig. 1A, Table IV ). CNVs in exons are more likely to have detrimental effects on gene products. Additionally, there is a clear enrichment of enhancer-and promoterassociated histone mark (H3K4Me1) in CTNNA3 CNVRs in the replication cohort, which is also conserved, as shown in the UCSC genome browser (Fig. 1B) , suggesting a loss of potential transcriptional regulation due to the deletion. This CNVR chr10:68383827-68407077 was found in 2 of 167 cases and 1 of 1573 controls (Table IV) . The CTNNA3 gene encodes a cadherinassociated protein. Conducting genomic annotation using the HaploReg (23) software package, we found that each of the above CNVRs harbors multiple SNPs overlapping with promoter/enhancer histone marks, protein binding sites, and transcription factor motifs (Supplemental Table I ), suggesting potentially altered transcriptional regulation of CTNNA3 and RBFOX1 resulting from the CNVs in these regions.
To check whether any of the significant CNVR associations were confounded by population stratification, we conducted PCA and performed logistic regression on the CNV status, including the first three principal components as covariates. All of the associations in Tables III and IV remained significant in both the discovery cohort and the replication cohort, with the exception of RBFOX1 in the replication cohort (Tables III, IV) . To tease out how population stratification affects the association of RBFOX1, we further examined its association in only those samples of European ancestry, in which we found significant association of RBFOX1 in both the discovery cohort (p = 0.00364) and the replication cohort (p = 0.00482). The meta-analysis yielded a p value of 7.35 3 10
25
( Fig. 2, Table IV , Supplemental Table II) .
The significant associations in both the discovery cohort and the replication cohort suggested little batch effect in our study. To further check for any batch effect, we combined the discovery cohort and the replication cohort, labeling the CTNNA3 deletion genotype as 1 2 for samples with either of the two CTNNA3 CNVRs and 2 2 for the rest of the samples. Then we examined whether there was an association between the CTNNA3 deletion genotype and food allergy via a Fisher exact test and permutation analysis to derive the empirical significance. We similarly tested the RBFOX1 deletion genotype with food allergy through permutation among the subjects of European ancestry only. The resulting empirical p values were 1.7 3 10 23 and 1.0 3 10 24 for
CTNNA3 and RBFOX1, respectively. Therefore, their associations with food allergy are not due to batch effect.
Next, we performed quantitative PCR (qPCR) to experimentally verify the CNVRs in CTNNA3 and RBFOX1 (Fig. 3) . We selected all cases with CNVs at either of these loci. To act as controls, we performed qPCR on randomly selected samples with no evidence of CNVs at these loci. The qPCR results confirmed the copy number status of all of the samples selected, thus validating our CNV analysis results for these two loci. 
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Deletions spanning an exonic sequence can directly affect transcription and translation of gene products. The CTNNA3 exonic deletion resulted in a frameshift mutation that is predicted to result in premature termination of transcription and subsequent protein degradation by the introduction of a downstream stop codon. We then examined the CTNNA3 protein level in EBV cell lines established from one case sample carrying the exonic deletion CNVR (Fig. 1A) and four other samples without CNV at this region. We observed a reduced CTNNA3 protein level in the deletion case sample on Western blot (Fig. 4) .
To further investigate the functional significance and biological role of CTNNA3 in the pathogenesis of food allergy, we conducted a CD63 basophil test in CTNNA3-KD mononuclear cells compared with controls. Changes in monocyte activation during the assay are reflective of IgE-dependent responses to allergen challenge. In our experiment, we used siRNA to mediate KD of CTNNA3, which resulted in a 70% reduction in CTNNA3 protein level, as confirmed by Western blot (Fig. 5B) . We then measured upregulation of CD63 and CD203c on cells upon PMA stimulation by FACS. Tetraspan Ag CD63 and CD203c are surface markers expressed on various myeloid cells, including basophils and monocytes, and they show an increased expression following exposure to allergen or anti-IgE Ab. In our experiment, both Ags were upregulated after activation with PMA (Fig. 5A) . The upregulation was more pronounced in CTNNA3-KD cells in comparison with control siRNA cells activated with PMA. Therefore, we conclude that reduced CTNNA3 expression leads to PMAinduced upregulation of CD63 and CD203C, suggesting increased sensitization to allergens.
Genes function collaboratively through genetic and physical interactions to contribute to disease etiology. Using Database for Annotation, Visualization, and Integrated Discovery (24), we tested whether the genes that are close to or harboring our significant CNVRs are enriched for certain functional categories. We used the genes that were close to significant overlapping CNVRs in Table III and those significant overlapping genes in Table IV as input for the analysis. The results showed that 7 of 10 input genes (CPSF3L, RBFOX1, PUSL1, GALNTL6, MACROD2, LUZP2, CTNNA3) fell into the functional categories of alternative splicing and splice variant, with nominal p values of 0.0035 and 0.0035, respectively. This is consistent with prevalent alternative splicing in the immune system (25, 26) .
Discussion
Genome-wide CNV analysis is an emerging method of assessing the genetic underpinnings of clinical disease that eliminates preconceptions of any particular candidate genes. Using this method, we identified genes of interest in food allergy.
HLA-B is a class I MHC molecule that displays intracellular peptides to T cells. Although not previously identified as a gene of interest in food allergy, HLA-B differences are seen in drug hypersensitivity reactions (27) and chronic idiopathic urticaria (28) . Moreover, region 6p21.33, in which HLA-B resides, is a susceptibility locus for subjects with environmental allergy (29) .
CTNNA3 encodes a structural cadherin important for cell-cell adhesion (30) . It is transcribed using multiple promoters, which produce alternate transcripts (31) . The importance of CTNNA3 in maintaining cell-cell adhesion may play a role in allergy. Impaired skin and airway barrier is associated with atopic disease susceptibility (reviewed in Ref. 32) . Electron microscope studies demonstrated impairment of this barrier in asthmatics compared with controls (33, 34) . In addition, reduced CTNNA3 levels were found in the bronchial biopsies of asthmatics, and they correlated inversely with eosinophil numbers (35) . Moreover, CTNNA3 SNPs were identified by a GWAS in Korean subjects with diisocyanate-induced occupational asthma (36) . Two of the CTNNA3 SNPs identified in the Korean study were subsequently confirmed in a study of Canadian workers with occupational asthma (37) . A recent GWAS demonstrated the association between SNP in CTNNA3 and response to glucocorticoid therapy in childhood asthma (38) .
The RBFOX1-ataxin-2 complex is considered important for RNA transport in neurons; furthermore, alterations lead to neuronal cytotoxicity (39) . Both human and animal model studies demonstrated the importance of RBFOX1 in neuronal development and regulation (40, 41) . Although the connection between neurologic stimulation and atopic disease remains to be elucidated, it is noteworthy that stress can exacerbate atopic dermatitis via substance P-dependent neurogenic inflammation (42, 43) .
Common variants have long been considered the major genetic determinants of common disease, playing a key role in disease etiology. However, as GWASs showed, even where large numbers of susceptibility loci have been identified, .100 genome-wide significant loci in the case of inflammatory bowel disease, the heritability explained by these loci is modest (44) . Accumulating evidence suggests an important contribution of rare variants, including rare CNVs, to the etiology of complex disease. Significant associations with CNVs were reported across multiple diseases, such as sporadic amyotrophic lateral sclerosis (45) , autism (46) , obesity (47) , congenital heart disease (48), and endometriosis (49). Riggs et al. (50) recently reviewed the impact of CNVs on autism. They concluded that, although CNVs may be individually rare, each accounting for no more than 1% of cases, when combined the overall CNV burden explains a significant proportion of disease variance, estimated to be between 5 and 10%. These rare CNVs usually present a higher risk than most of the common variants. Therefore, it is important to identify and further characterize these rare structural variants to fully understand their clinical significance.
To the best of our knowledge, our analysis is the first to investigate CNVs associated with food allergy on a genome-wide scale. We used a hypothesis-free, unbiased approach. Genes identified in the discovery cohort were validated in an independent cohort genotyped on a different platform, strengthening the validity of our discoveries. In addition, we showed the siRNA KD of CTNNA3 results in increased degranulation, further demonstrating the biological importance of CTNNA3 in allergy.
Although these results are important, there are certain limitations to our study. First, the number of cases analyzed was relatively small for a genome-wide study. Food allergy is a heterogeneous condition that requires stringent phenotyping criteria to reduce misdiagnosis. As a result, 47% of potential cases were excluded from our analysis following chart review. However, we included a relatively large number of controls, leading to a high control/case ratio of 10, which increases statistical power when the effect of exposure is large and when the prevalence of exposure among controls is low (51) (52) (53) . In this study, the exposure is the presence of the CNV. Rare variants, including CNVs, usually have a greater effect size than do common variants, and the population frequency of rare variants is very low. Because of the moderate to large effect size of rare CNVs and the high control/case ratio, we were able to detect multiple significant associations in our cohort. However, we would miss the association of CNVs with a lower effect size (e.g., a type II error). With a larger cohort, more CNV areas of interest may have been identified. Given that we were able to demonstrate significant CNV frequency differences between cases and controls despite our sample size, we surmise that the p value attained in a larger sample size would be smaller. A second limitation is that we were unable to generate a sufficiently large cohort of food monoallergic patients to perform subgroup analyses. Third, false associations can be seen in CNV analysis, as discussed by Craddock et al. (54) . In this regard, we note that the CNVs that we reported to be of clinical significance were experimentally validated. Finally, CNV association analysis is affected by choices of normalization and probe weighting, and optimal choice can vary (54) . In summary, we described a novel approach to assess for genetic susceptibility to food allergy. By working backward from genotype to phenotype, we identified two intriguing CNV variants that may play a role in food allergy. These variants are of unclear significance, and more functional studies are required to establish their mechanism of action. However, we also envision that more advanced computational algorithms may aid in determining their pathogenicity and identify other loci and gene networks of clinical interest. 
